Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M

Syndax Pharmaceuticals Inc

2026-Q1 EPS reported -$0.48 revenue$64,864,000

Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.
Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).
Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.
FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.
Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Syndax Pharmaceuticals Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $64.9 million.

Period: first quarter ended March 31, 2026
Revenue: Total revenue of $64.9 million
Result: reported results

Exact text from the filing

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-197124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.